---
schema_version: "secwatch.filing_event.v1"
accession: "0002007919-25-000020"
form_type: "8-K"
ticker: "INBX"
cik: "0002007919"
company_name: "Inhibrx Biosciences, Inc."
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T16:49:49.452214+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Inhibrx reports FY2024 net income of $1.7B driven by spin-off gain; secures $100M loan

## Summary
- Net income of $1.7B (EPS $114.01 basic) vs net loss of $241.4M in FY2023; gain from Sanofi INBRX-101 sale.
- Cash of $152.6M at Dec 31, 2024; after $100M Oxford loan in Jan 2025, $230.5M as of Feb 28, 2025.
- R&D expense $203.7M (FY2024) vs $191.6M; includes $25.9M stock option acceleration from spin-off.
- G&A expense $127.9M (FY2024) vs $29.4M; includes $68.1M spin-off costs and $15.2M option acceleration.
- Ozekibart Phase 1 CRC data: 1 CR, 3 PRs, median PFS 7.85 mo; expansion cohort enrolling up to 50 patients.

## SEC filing metadata
- accession: 0002007919-25-000020
- form_type: 8-K
- ticker: INBX
- cik: 0002007919
- company_name: Inhibrx Biosciences, Inc.
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2007919/000200791925000020/0002007919-25-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2007919/000200791925000020/inhibrx-20250317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002007919-25-000020
- JSON: https://secwatch.observer/filing/0002007919-25-000020.json
- Plain text: https://secwatch.observer/filing/0002007919-25-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.